5.44

2.84% +0.15

Terns Pharmaceuticals Inc (TERN)

Overview News Price History Option Chain Financials Discussions Forecast

Terns Pharmaceuticals Inc stock is currently priced at $5.44, with a 24-hour trading volume of 562.12K. It has seen a +2.84% increased in the last 24 hours and a -9.33% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.24 pivot point. If it approaches the $5.50 resistance level, significant changes may occur.

Previous Close:

$5.29

Open:

$5.39

24h Volume:

562.12K

Market Cap:

$351.83M

Revenue:

Net Income/Loss:

$-90.21M

P/E Ratio:

-4.2171

EPS:

-1.29

Net Cash Flow:

$-67.44M

1W Performance:

+10.79%

1M Performance:

-9.33%

6M Performance:

+11.93%

1Y Performance:

-57.83%

1D Range:

$5.21

$5.57

52W Range:

$3.26

$13.51

Terns Pharmaceuticals Inc Stock (TERN) Company Profile

Name

Terns Pharmaceuticals Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

650 525 5535

Address

1065 East Hillsdale Boulevard, Suite 100, Foster City

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

TERN's Discussions on Twitter

Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-23	Initiated	BMO Capital Markets	Outperform
Feb-14-23	Initiated	JMP Securities	Mkt Outperform
Feb-07-23	Initiated	UBS	Buy
Sep-12-22	Initiated	H.C. Wainwright	Neutral
Sep-14-21	Resumed	Goldman	Buy
Mar-02-21	Initiated	Cowen	Outperform
Mar-02-21	Initiated	Goldman	Buy
Mar-02-21	Initiated	JP Morgan	Overweight

View All

Terns Pharmaceuticals Inc Stock (TERN) Latest News

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire Inc.

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

GlobeNewswire Inc.

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

GlobeNewswire Inc.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

GlobeNewswire Inc.

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

GlobeNewswire Inc.

Terns Pharmaceuticals Inc Stock (TERN) Financials Data

Terns Pharmaceuticals Inc (TERN) Net Income 2024

TERN net income (TTM) was -$90.21 million for the quarter ending December 31, 2023, a -49.49% decrease year-over-year.

Terns Pharmaceuticals Inc (TERN) Cash Flow 2024

TERN recorded a free cash flow (TTM) of -$67.44 million for the quarter ending December 31, 2023, a -36.57% decrease year-over-year.

Terns Pharmaceuticals Inc (TERN) Earnings per Share 2024

TERN earnings per share (TTM) was -$1.27 for the quarter ending December 31, 2023, a +30.60% growth year-over-year.

Terns Pharmaceuticals Inc Stock (TERN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Vivo Opportunity, LLC	10% Owner	Apr 02 '24	Sale	6.65	101,480	674,842	272,722
Vivo Opportunity, LLC	10% Owner	Apr 01 '24	Sale	6.99	181,117	1,266,008	275,772

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.